Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library

GHK-Cu vs SNAP-8

GHK-Cu and SNAP-8 are both short peptides used in topical skin products, but they are studied for different purposes and have different depths of evidence 2,8. GHK-Cu is a copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a peptide present in human plasma, saliva and urine, and it has been tested in wound-healing and skin studies in animals and people 2,4,5. SNAP-8 is acetyl octapeptide-3, a synthetic eight-amino-acid cosmetic ingredient studied for facial wrinkle appearance, only inside multi-ingredient products in the studies located 6,7,8. Neither is an FDA-approved drug 11.

Unbranded reference vial illustrating GHK-Cu; not an actual product
GHK-Cu
Not approved — research use only
Unbranded reference vial illustrating SNAP-8; not an actual product
SNAP-8
Not approved — research use only

Side by side

FieldGHK-CuSNAP-8
ClassCopper(II) complex of a tripeptide (Gly-His-Lys); PubChem lists prezatide copper, C14H23CuN6O4+ 1,2Synthetic acetylated octapeptide (acetyl octapeptide-3); PubChem lists C41H70N16O16S 9
Origin and structureGHK occurs in human plasma, saliva and urine and declines with age; it is proposed to act as a copper complex 2Designed cosmetic peptide; no natural source is described in the sources reviewed 9
Proposed mechanismReviews describe effects on collagen, glycosaminoglycan and metalloproteinase activity and on gene expression in skin cells 2,3Marketed for facial wrinkle appearance; no mechanism was established in the primary studies located, which tested it only within mixed formulations 6,7
Half-lifeNot located in the sources reviewedNot located in the sources reviewed
Highest human trial phaseOne small randomised study of 13 patients after CO2 laser resurfacing 4No registered trials; evidence is two cosmetic studies of multi-ingredient microneedle patches 6,7,10
FDA statusNot FDA-approved as a drug; used as a cosmetic ingredient 2. GHK-Cu for injectable routes is listed among withdrawn category 2 compounding nominations, while GHK-Cu except for injectable routes was added back to 503A category 1 on 14 May 2026 11,12Not FDA-approved; no openFDA drug label for acetyl octapeptide-3 (queried 24 October 2026) and not in any 503A nomination category as updated 14 May 2026 12,13
Published human outcomesIn 13 patients after CO2 laser resurfacing, blinded and computer assessment found no significant difference in redness or wrinkles versus the regimen without GHK-Cu, while questionnaire-rated skin quality differed 4A 12-week study of a patch containing several actives reported measured reductions in fine lines, and a 24-subject patch study reported wrinkle changes versus a hyaluronic-acid-only placebo; neither isolates SNAP-8 6,7
Safety signalsFDA notes immunogenicity risk from aggregation and impurities for injectable GHK-Cu and limited human data 11The two patch studies reported no skin reactions, but tested mixed products rather than the peptide alone 6,7
WADA statusNot named on the 2026 Prohibited List 14Not named on the 2026 Prohibited List 14
Who funded the evidenceTwo of the main reviews are by authors affiliated with a company connected to the peptide's commercial use 2,3Cosmetic and dermatology groups in Turkey and South Korea; the studies tested commercial patch products 6,7

GHK-Cu: what the data says

GHK is a tripeptide present in human plasma, saliva and urine whose levels decline with age, and reviews propose that it acts as a complex with copper 2. Those reviews, written by authors connected to its commercial use, describe effects on collagen and glycosaminoglycan synthesis, metalloproteinase activity and gene expression in skin cells and animal models 2,3.

Controlled data are thinner. In a randomised study of 13 patients after CO2 laser skin resurfacing, blinded evaluators and computer analysis found no significant difference in redness resolution, wrinkles or overall skin quality between regimens with and without GHK-Cu, although patient questionnaire ratings of overall skin quality differed 4. In 72 rats after anterior cruciate ligament reconstruction (animal data), intra-articular GHK-Cu was associated with less side-to-side knee laxity at 6 weeks but no significant difference at 12 weeks 5.

SNAP-8: what the data says

SNAP-8 is the cosmetic name for acetyl octapeptide-3, a synthetic eight-amino-acid peptide 9. In the studies located, it was never tested on its own: both are evaluations of microneedle patches containing several active ingredients 6,7.

In a 12-week single-centre study, hyaluronic-acid microneedle patches containing acetyl octapeptide-3 along with an arginine/lysine polypeptide, palmitoyl tripeptide-5, adenosine and seaweed extracts were applied near the eyes and on the forearm of people with aged skin; the authors reported measured reductions in fine lines and changes in hydration, density and thickness, with no skin reactions 6. In a 24-subject comparative study, a dissolving patch containing acetyl octapeptide-3, a vitamin C derivative and a lipid compound was compared with a hyaluronic-acid-only placebo patch and reported eye-wrinkle and elasticity changes over 28 days 7. Because the formulations contain multiple actives, neither study shows what acetyl octapeptide-3 contributes 6,7.

Key research differences

  • Natural occurrence: GHK is found in human plasma, saliva and urine 2, whereas SNAP-8 is a designed cosmetic peptide with no natural source described 9.
  • Metal complex: GHK-Cu contains copper as part of the molecule 1, while SNAP-8 is a plain acetylated peptide 9.
  • Isolation of effect: GHK-Cu has been tested against a control regimen in a small randomised study 4, whereas SNAP-8 appears only inside multi-ingredient patches 6,7.
  • FDA compounding standing: GHK-Cu appears in the FDA's 503A lists, in category 1 for non-injectable routes and among withdrawn category 2 nominations for injectable use 11,12; SNAP-8 appears in no category 12.

Where the evidence is limited

No study has compared GHK-Cu with SNAP-8. The GHK-Cu literature is dominated by narrative reviews from authors connected to its commercial use, and the one controlled human study located was small and largely negative on objective measures 2,3,4. The SNAP-8 studies test finished cosmetic products containing several actives, so any measured change cannot be attributed to the peptide 6,7. Cosmetic ingredients are not subject to premarket FDA review in the United States, so their absence from drug databases says nothing about effect 12,13.

Frequently asked questions

Is SNAP-8 the same as acetyl octapeptide-3?
Yes. SNAP-8 is the trade name for acetyl octapeptide-3, listed in PubChem as an eight-amino-acid acetylated peptide 9.
Has GHK-Cu been tested in a controlled human study?
Yes, but in small numbers. In 13 patients after laser resurfacing, objective measures showed no significant difference versus the comparison regimen 4.
Can GHK-Cu and SNAP-8 be compared directly?
Not on current evidence. No head-to-head study exists, and SNAP-8 has only been studied inside multi-ingredient products 6,7.
What is GHK-Cu's status in the FDA compounding lists?
GHK-Cu except for injectable routes was added back to 503A category 1 on 14 May 2026, while injectable GHK-Cu is listed among withdrawn category 2 nominations with immunogenicity concerns 11,12.

References

  1. Prezatide copper (CID 71587328): compound summary and computed properties PubChem. 2026
  2. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration BioMed Research International. 2015
  3. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data International Journal of Molecular Sciences. 2018
  4. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin Archives of Facial Plastic Surgery. 2006
  5. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction Journal of Orthopaedic Research. 2015
  6. Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study Journal of Cosmetic Dermatology. 2020
  7. Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities Annals of Dermatology. 2024
  8. The human tri-peptide GHK and tissue remodeling Journal of Biomaterials Science, Polymer Edition. 2008
  9. Acetyl octapeptide-3 (CID 76283482): compound summary and computed properties PubChem. 2026
  10. ClinicalTrials.gov registry search: SNAP-8 and acetyl octapeptide-3 (no registered studies returned, searched 24 October 2026) ClinicalTrials.gov. 2026
  11. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026) FDA (Human Drug Compounding). 2026
  12. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) FDA. 2026
  13. openFDA drug label query for acetyl octapeptide-3 as substance name (no matches, queried 24 October 2026) openFDA. 2026
  14. Prohibited List (2026 List, in force 1 January 2026) World Anti-Doping Agency. 2026

For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement. This page compares published research and is not medical advice or a recommendation.